The U.S. Food and Drug Administration (FDA) has cleared the BioPhotas Celluma device for an additional indication for use: treating facial wrinkles. The Celluma was previously cleared for seven separate indications, including the treatment of acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation.
The Celluma uses three wavelengths of light energy simultaneously—modulated with proprietary electronic algorithms—to treat a variety of skin, muscle and joint conditions. Its patented flexible design molds to the body, allowing the light to be absorbed more effectively. In a clinical study reviewed by three board certified dermatologists, the device was shown to have produced a lasting and quantifiable reduction in facial wrinkles 12 weeks after the completion of a four-week treatment regimen.
In support of this new FDA clearance, BioPhotas has launched a new website (www.biophotas.com), which explains low-level light therapy (LLLT) and the Celluma in great detail, highlighting the use of the Celluma in treating acne and wrinkles as well as aches and pain.
Photo copyright Getty Images.